Abstract
Late-onset retinal degeneration (L-ORD) is a rare autosomal dominant retinal dystrophy, characterised by extensive sub-retinal pigment epithelium (RPE) deposits, RPE atrophy, choroidal neovascularisation and photoreceptor cell death associated with severe visual loss. L-ORD shows striking phenotypic similarities to age-related macular degeneration (AMD), a common and genetically complex disorder, which can lead to misdiagnosis in the early stages. To date, a single missense mutation (S163R) in the C1QTNF5 gene, encoding C1q And Tumor Necrosis Factor Related Protein 5 (C1QTNF5) has been shown to cause L-ORD in a subset of affected families. Here, we describe the identification and characterisation of three novel pathogenic mutations in C1QTNF5 in order to elucidate disease mechanisms. In silico and in vitro characterisation show that these mutations perturb protein folding, assembly or polarity of secretion of C1QTNF5 and, importantly, all appear to destabilise the wildtype protein in co-transfection experiments in a human RPE cell line. This suggests that the heterozygous mutations in L-ORD show a dominant negative, rather than a haploinsufficient, disease mechanism. The function of C1QTNF5 remains unclear but this new insight into the pathogenetic basis of L-ORD has implications for future therapeutic strategies such as gene augmentation therapy.
Highlights
Recent advances in retinal gene therapy emphasise the importance of understanding pathogenetic mechanisms in inherited retinal dystrophies[1]
These studies further suggested that the S163 residue forms an intermolecular hydrogen bond network involved in tethering the globular globular complement 1q/tumor necrosis factor-like (gC1q) heads together into a stable trimer, which is weakened by the R163 founder mutation[11,12]
V:VI and V:VII showed a significant delay in dark adaptometry, an early phenotypic marker of Late-onset retinal degeneration (L-ORD), but had minimal retinal changes, visual acuities of 6/6, and reported no loss of central vision in their sixth decade
Summary
Recent advances in retinal gene therapy emphasise the importance of understanding pathogenetic mechanisms in inherited retinal dystrophies[1]. A crystal structure of the trimeric gC1q domain[11,12], suggested that the high molecular weight form is an octadecamer, consisting of a bouquet-like arrangement of six gC1q trimers tethered by their collagenous stalks, resembling other C1q/TNF family members such as C1q and adiponectin. These studies further suggested that the S163 residue forms an intermolecular hydrogen bond network involved in tethering the globular gC1q heads together into a stable trimer, which is weakened by the R163 founder mutation[11,12]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.